Home › Therapeutic areas › Oncology › Glioblastoma
Glioblastoma (18 companies)
Companies with an active program in Glioblastoma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| DRTS | Alpha Tau Medical | Oncology | 1 | Phase 2 | $1.27B | 6 |
| BDTX | Black Diamond Therapeutics | Oncology | 1 | Phase 2 | $99.7M | 4 |
| CADL | Candel Therapeutics | Oncology | 1 | Phase 3 | $670M | 4 |
| CLRB | Cellectar Biosciences | Oncology | 1 | Phase 2 | $11.8M | 6 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $137M | 15 |
| FBIO | Fortress Biotech | DermatologyHematology+3 Rare | 1 | Approved | $61.7M | 12 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 2 | Approved | $9.15B | 16 |
| INAB | IN8bio | ImmunologyOncology | 2 | Phase 1 | $10.0M | 4 |
| INBX | Inhibrx Biosciences | Oncology | 1 | NDA Submitted | $1.24B | 6 |
| KAPA | Kairos Pharma | Oncology | 1 | Phase 2 | — | 13 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 3 | Phase 2 | $82.0M | 13 |
| MAIA | MAIA Biotechnology | Oncology | 1 | Phase 3 | $64.5M | 7 |
| MDNAF | Medicenna Therapeutics | Oncology | 1 | Phase 2 | $29.5M | 10 |
| MBRX | Moleculin Biotech | Oncology | 3 | Phase 2 | — | 8 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 1 | Phase 3 | $719M | 9 |
| PYPD | PolyPid | Infectious DiseaseOncology | 1 | NDA Submitted | $125M | 3 |
| TNGX | Tango Therapeutics | Oncology | 1 | Phase 1 | $3.63B | 4 |
| TLX | Telix Pharmaceuticals | Oncology | 3 | Approved | $3.27B | 25 |
No companies match.